
|Videos|March 20, 2014
The Utility of Hyperthermic Intraperitoneal Chemotherapy
Author(s)Valerie Francescutti, MD, FRCSC
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
Advertisement
Clinical Pearls
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
- HIPEC involves removing all cancer from a patient’s abdominal cavity and providing heated chemotherapy for the management of any microscopic tumors
- Indications for HIPEC include colorectal cancer that has resulted in peritoneal metastases, appendiceal cancer, and peritoneal mesothelioma
- At RPCI, 50-60% of patients treated with HIPEC have appendiceal or colorectal cancers
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































